{
    "nct_id": "NCT04590872",
    "official_title": "A Pilot Study to Evaluate the Safety and Feasibility of Autologous Tolerogenic Dendritic Cells Loaded With Proinsulin Peptide (C19-A3) in Patients With Type 1 Diabetes",
    "inclusion_criteria": "* Willingness to undergo leukapheresis\n* Willingness to be followed for about 2 years post-prime dose\n* For participants who have a personal continuous glucose monitoring device (CGMD): Willingness to wear a second CGMD during mandated study CGMD visits\n* Diagnosis of type 1 diabetes based on American Diabetes Association (ADA) criteria\n* Historical presence of at least one type-1 diabetes associated autoantibody\n\n  * GAD specific autoantibodies (glutamic acid decarboxylase autoantibodies [GADA])\n  * Islet cell cytoplasmic autoantibodies (ICA)\n  * Islet-antigen 2 specific autoantibody (IA-2A)\n  * Zinc transporter 8 specific autoantibody (ZNT8A); and/or\n  * Insulin autoantibody (IAA) (must have been obtained within 7 days of initiating exogenous insulin replacement therapy)\n* Time from diagnosis to screening mixed meal tolerance test (MMTT) must be >= 1 year but =< 4 years\n* Stable glycemic control per participant's physician\n* HbA1c =< 7.5% (=< 58 mmol/mol)\n* Non-fasting C-peptide > 0.017 nmol/L\n* Stimulated peak C-peptide levels > 0.2 nmol/L from a 2-hour screening MMTT\n* Positive for *04:01 allele, *04:02 allele and/or *04:04 allele at the human leukocyte antigen (HLA)-DRB1 gene locus\n* Does not possess the protective HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype\n* Adequate self-assessment of blood glucose values and recording of glucose values, and administered insulin doses as deemed sufficient by the participant's physician\n* No diagnosis of type 1 diabetes related microvascular/macrovascular complications (e.g. nephropathy, retinopathy and neuropathy)\n* Deemed acceptable for autologous cell collection (i.e. leukapheresis)\n* Only for those who are naive to CGMD use: Deemed able to correctly use a CGM device following training session with a certified diabetes educator and manufacturer representative\n* Must meet organ function criteria\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 45 Years",
    "exclusion_criteria": "* Other investigational agents, biologics\n* Anti-inflammatory therapy\n\n  * Exception: Over-the-counter (OTC) anti-inflammatory agents (e.g. ibuprofen, Tylenol) are generally allowed. However, those requiring chronic OTC anti-inflammatory agents and unable to stop during mandated CGMD study visits will be excluded\n* Systemic corticosteroids within 28 days prior to leukapheresis\n* Systemic immunosuppressive therapy (e.g. cyclosporine-A, cyclophosphamide)\n* Monoclonal antibody therapy\n* Allergen immunotherapy within 28 days prior to leukapheresis\n* Vaccine(s) within 28 days prior to leukapheresis\n* Prior allogeneic organ transplant\n* Beta-cell stimulants (e.g. sulfonylureas such as glimepiride), glucagon-like peptide-1 agonists, dipeptidyl peptidase-IV inhibitors (exception: Those with acute exposure to these agents during T1D misdiagnosis may be permitted per PI discretion)\n* Insulin sensitizers (e.g. metformin, thiazolidinediones) within 2 months of leukapheresis\n* History of insulin sensitizer use (e.g. metformin, thiazolidinediones) â‰¥ 2 months\n* Other autoimmune/inflammatory disorders (exceptions: (i) Type 1 diabetes. (ii) Asymptomatic patients with incidental autoantibody titres may be permitted per PI discretion)\n* Other autoimmune/inflammatory disorders (exception type 1 diabetes)\n* Active infection requiring antibiotics and/or anti-virals\n* Known history of HIV, HBV, HCV, HTLV, syphilis\n* History of positive purified protein derivative (PPD) skin test\n* History of atopy requiring systemic treatment and/or history of severe allergic reactions\n* History or current malignancy\n* Unstable cardiac disease\n* History of vascular disease (e.g. deep vein thrombosis, stroke)\n* Clinically significant uncontrolled illness\n* Females only: pregnant or breastfeeding",
    "miscellaneous_criteria": ""
}